Systematic review on hormone receptor testing in breast cancer

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 3, 2012, Pages 214-263

  Nofech Mozes, Sharon ^a   Vella, Emily T ^b   Dhesy Thind, Sukhbinder ^b   Hagerty, Karen L ^c   Mangu, Pamela B ^c   Temin, Sarah ^c   Hanna, Wedad M ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

breast cancer; estrogen; hormone receptors; immunohistochemistry; practice guideline; quality assurance

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; RECEPTOR ANTIBODY; TAMOXIFEN;

ANTIGEN RETRIEVAL; ARTICLE; ASPIRATION BIOPSY; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONSENSUS DEVELOPMENT; DEXTRAN COATED CHARCOAL LIGAND BINDING ASSAY; DISEASE SPECIFIC SURVIVAL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED PRACTICE; FLOW CYTOMETRY; FROZEN SECTION; GENE EXPRESSION PROFILING; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, HORMONE-DEPENDENT; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY CONTROL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RESEARCH DESIGN; SPECIMEN HANDLING; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84859899487     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318234aa12     Document Type: Article

References (224)

1. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907-922.
2. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28: 2784-2795.
3. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48-e72.
4. Nofech-Mozes S, Vella ET, Dhesy-Thind S, et al, Guideline on Hormone Receptor Testing in Breast Cancer. Available at: http://www.cancercare.on.ca/ toolbox/qualityguidelines/clin-program/path labebs/; 2011.
5. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174. (Pubitemid 8054849)
6. Andre F, Conforti R, Tomasic G, et al, Predictive values of estrogen receptor (ER) expression and molecular subclassification for the benefit of adjuvant anthracycline-based chemotherapy (CT) in two randomized trials. Presented at the 2006 San Antonio Breast Cancer Symposium. December 14-17, 2006; San Antonio, TX.
7. Baehner F, Habel LA, Quesenberry CP, et al, Quantitative RTPCR analysis of ER and PR by Oncotype DX indicates distinct and different associations with prognosis and prediction of tamoxifen benefit. Presented at the 2006 San Antonio Breast Cancer Symposium. December 14-17, 2006; San Antonio, TX.
8. Baehner F, Watson D, Ballard JT, et al, Gene expression by standardized quantitative RT-PCR in the special histologic subtypes of estrogen receptor positive invasive breast cancer. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
9. Baker J, Salter J, Liu ML, et al, Measurement of gene expression using tissue microarray cores of paraffin embedded breast cancer tissue. Presented at the 2005 San Antonio Breast Cancer Symposium. December 8-11, 2005; San Antonio, TX.
10. Chapman JW, Jasani B, Ibrahim M, et al, Standardization of estrogen and progesterone receptor assay values. Presented at the 2005 San Antonio Breast Cancer Symposium. December 8-11, 2005; San Antonio, TX.
11. Chung GG, Zerkowski MP, Ghosh S, et al, Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Presented at the 2006 San Antonio Breast Cancer Symposium. December 14-17, 2006; San Antonio, TX.
12. Faratian D, Kay C, Campbell F, et al, Automated image analysis for high-throughput quantitative detection of ER and PgR expression levels in large-scale clinical studies: the TEAM trial experience. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
13. Habel LA, Achacoso N, Maddala T, et al, Estrogen receptor and breast cancer survival in a Kaiser permanente population-based study: comparison of quantitative reverse transcriptase polymerase chain reaction and immunohistochemistry. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
14. Hoyt CC, Gossage K, Levenson RM, et al, Multiplexed immunohistochemical quantitative molecular phenotyping via multispectral imaging and automated segmentation. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
15. Kim C, Tang G, Baehner F, et al, A comparison of estrogen receptor (ER) measurement by three methods in node negative, estrogen receptor (ER) positive breast cancer: ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PC. Presented at the 2006 San Antonio Breast Cancer Symposium. December 14-17, 2006; San Antonio, TX.
16. Larionov AA, Dixon JM, White S, et al, Repeatability and sources of uncertainty in relative real time PCR gene expression measurements in breast cancer biopsies. Presented at the 2005 San Antonio Breast Cancer Symposium. December 8-11, 2005; San Antonio, TX.
17. Litwiniuk M, Filas V, Breborowicz J, Expression of estrogen receptors b in triple negative breast cancer. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
18. Liu Z, Wu J, Ping B, et al, Immunohistochemical expression of CK5/6, CK17, ERb in triple negative breast cancer patients. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
19. Shak S, Baehner F, Palmer G, et al, Relationship between proliferation genes and expression of hormone and growth factor receptors: quantitative RT-PCR in 10,618 breast cancers. Presented at the 2006 San Antonio Breast Cancer Symposium. December 14-17, 2006; San Antonio, TX.
20. Shak S, Baehner F, Palmer G, et al, Subtypes of breast cancer defined by standardized quantitative RT-PCR analysis of 10,618 tumors. Presented at the 2006 San Antonio Breast Cancer Symposium. December 14-17, 2006; San Antonio, TX.
21. Siland H, Skaland I, Van Diermen B, et al, Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
22. Thorat M, Morimiya A, Sledge G, et al, Characterization of estrogen receptor positive breast cancers: gene expression analysis of archived tumours. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
23. Uzan C, Andre F, Veronique S, et al, Fine needle aspiration cytology material is highly suitable for mRNA extraction and subsequent molecular analysis of breast cancer. Presented at the 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX.
24. Van Laere SJ, Huyglen V, Van den Eynden GG, et al, Comparison of different immunohistochemical quantification techniques for estrogen receptor alpha and progesterone receptor with a qRT-PCR-based "ER modulated gene signature" for detection of hormone receptor dependent breast cancer. Presented at the 2006 San Antonio Breast Cancer Symposium. December 14-17, 2006; San Antonio, TX.
25. Watson D, Palmer G, Baker J, et al, The impact on the recurrence score due to patient variation in the quantitative expression of individual genes or gene groups. Presented at the 2006 San Antonio Breast Cancer Symposium. December 14-17, 2006; San Antonio, TX.
26. British Columbia Cancer Agency Cancer Management Guidelines. Diagnostic pathology [Internet]. Vancouver, BC: BC Cancer Agency; 2005 [cited August 6, 2008]. Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/ Breast/Diagnosis/DiagnosticPathology.htm.
27. National Breast and Ovarian Cancer Centre, Australian Cancer Network. The pathology reporting of breast cancer: a guide for pathologists, surgeons, radiologists, and oncologists [Internet]. 3rd ed. Surry Hills, NSW, Australia: National Breast and Ovarian Cancer Centre; 2008 [cited August 6, 2008]. Available at: http://www.cancer.org.au/File/HealthProfessionals/ Clinical%20Guidelines/Pathology-reporting-breastcancer-3rdEd2008.pdf.
28. Marchionni L, Wilson RF, Marinopoulos SS, et al. Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep Technol Assess (Full Rep). 2007;160:1-105.
29. Pertschuk LP, Feldman JG, Kim YD, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996;77:2514-2519.
30. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-1581. (Pubitemid 44680908)
31. Alberts SR, Ingle JN, Roche PR, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer. 1996;78:764-772. (Pubitemid 26268606)
32. Andersen J, Thorpe SM, Rose C, et al. Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. Acta Oncol. 1991;30:685-690.
33. Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74: 1445-1451. (Pubitemid 26370738)
34. Biesterfeld S, Schroder W, Steinhagen G, et al. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. Anticancer Res. 1997;17(6D):4723-4729. (Pubitemid 28081772)
35. Chebil G, Bendahl PO, Idvall I, et al. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer-clinical associations and reasons for discrepancies. Acta Oncol. 2003;42:719-725. (Pubitemid 37445291)
36. de Mascarel I, Soubeyran I, Macgrogan G, et al. Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Concordance with biochemical assay and prognostic significance. Appl Immunohistochem. 1995;3:222-231.
37. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000;89:111-117. (Pubitemid 30185917)
38. Ferno M, Andersson C, Fallenius G, et al. Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. Acta Oncol. 1996;35: 17-22. (Pubitemid 26084845)
39. Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer. 2005;103:164-173. (Pubitemid 39665470)
40. Grabau DA, Thorpe SM, Knoop A, et al. Immunohistochemical assessment of oestrogen and progesterone receptors: correlations with the DCC method and clinical oucome in primary breast cancer patients. Breast. 2000;9:208-217.
41. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481. (Pubitemid 29220854)
42. Iwase H, Zhang Z, Omoto Y, et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol. 2003; 52(Suppl 1):S34-S38. (Pubitemid 37047022)
43. Macgrogan G, Soubeyran I, de MI, et al. Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas. A correlative study of 942 cases. Appl Immunohistochem. 1996;4:219-227.
44. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545-1554. (Pubitemid 39627082)
45. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer. 2004;11:267-275.
46. Thomson CS, Twelves CJ, Mallon EA, et al. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast. 2002;11:419-429. (Pubitemid 35469501)
47. Younes M, Laucirica R, Miller CC, et al. The prognostic value of estrogen receptor immunocytochemistry (ERICA) in breast cancer does not depend on the immunostaining intensity. Breast Dis. 1996;9:157-170. (Pubitemid 26270656)
48. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24: 5637-5644. (Pubitemid 46631303)
49. Horii R, Akiyama F, Ito Y, et al. Assessment of hormone receptor status in breast cancer. Pathol Int. 2007;57:784-790. (Pubitemid 350060601)
50. Esteban JM, Ahn C, Battifora H, et al. Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. J Cell Biochem Suppl. 1994;19: 138-145. (Pubitemid 24306460)
51. Zidan A, Brown JSC, Peston D, et al. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol. 1997;50:27-29. (Pubitemid 27060200)
52. Anania G, Bazzocchi M, Di LC, et al. Percutaneous large core needle biopsy versus surgical biopsy in the diagnosis of breast lesions. Int Surg. 1997;82:52-55. (Pubitemid 27243667)
53. Jacobs TW, Siziopikou KP, Prioleau JE, et al. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol. 1998;11:259-264. (Pubitemid 28131535)
54. Douglas-Jones AG, Collett N, Morgan JM, et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol. 2001;54:951-955. (Pubitemid 34032891)
55. Smyczek-Gargya B, Krainick U, Muller-Schimpfle M, et al. Largecore needle biopsy for diagnosis and treatment of breast lesions. Arch Gynecol Obstet. 2002;266:198-200. (Pubitemid 36056592)
56. Connor CS, Tawfik OW, Joyce AJ, et al. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg. 2002;184: 322-324. (Pubitemid 35287351)
57. Taucher S, Rudas M, Gnant M, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer. 2003;10: 91-98. (Pubitemid 36457240)
58. Al Sarakbi WA, Salhab M, Thomas V, et al. Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surg Oncol. 2005;2: 15-18.
59. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Archiv. 2005;446:489-496. (Pubitemid 40884281)
60. Badoual C, Maruani A, Ghorra C, et al. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions. Breast. 2005;14:22-27. (Pubitemid 40197823)
61. Cavaliere A, Sidoni A, Scheibel M, et al. Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett. 2005;218:117-121. (Pubitemid 40082708)
62. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23:5148-5154. (Pubitemid 46224023)
63. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast. 2006;15: 167-172. (Pubitemid 44268916)
64. Cahill RA, Walsh D, Landers RJ, et al. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann Surg Oncol. 2006;13:45-51. (Pubitemid 43117644)
65. Usami S, Moriya T, Amari M, et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol. 2007;37:250-255. (Pubitemid 47090677)
66. Wood B, Junckerstorff R, Sterrett G, et al. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions. Pathology. 2007;39:391-395. (Pubitemid 47221462)
67. Hodi Z, Chakrabarti J, Lee AH, et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol. 2007;60: 299-302. (Pubitemid 46447747)
68. Sutela A, Vanninen R, Sudah M, et al. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Acta Oncol. 2008;47:38-46.
69. Garimella V, Long ED, O'Kane SL, et al. Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer. Acta Oncol. 2007;46:204-207.
70. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80: 1943-1949. (Pubitemid 32012762)
71. Gillett CE, Springall RJ, Barnes DM, et al. Multiple tissue core arrays in histopathology research: a validation study. J Pathol. 2000;192:549-553.
72. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249-2256. (Pubitemid 33104278)
73. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723-728. (Pubitemid 34457006)
74. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol. 2003;16:79-84. (Pubitemid 36152690)
75. Sapino A, Marchio C, Senetta R, et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Archiv. 2006;449:288-296. (Pubitemid 44367968)
76. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, et al. Semiquantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol. 2007;60:397-404. (Pubitemid 46596559)
77. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray-based assessment of outcome. J Clin Oncol. 2007; 25:5418-5425. (Pubitemid 350232218)
78. Quraishi I, Rishi M, Feldman M, et al. Clinical validation of breast cancer biomarkers using tissue microarray technology. Appl Immunohistochem Mol Morphol. 2007;15:45-49. (Pubitemid 46673315)
79. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1327. (Pubitemid 35373567)
80. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005; 97:1808-1815. (Pubitemid 43033901)
81. Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006;12:4614-4618. (Pubitemid 44297812)
82. Pinder SE, Wencyk PM, Naylor HE, et al. The assessment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: method, preliminary results and prognostic associations. Cytopathology. 1995;6:316-324.
83. Schmitt FC, Bento MJ, Amendoeira I. Estimation of estrogen receptor content in fine-needle aspirates from breast cancer using the monoclonal antibody 1D5 and microwave oven processing: correlation with paraffin embedded and frozen sections determinations. Diagn Cytopathol. 1995;13:347-351.
84. Leung SW, Bedard YC. Estrogen and progesterone receptor contents in ThinPrep-processed fine-needle aspirates of breast. Am J Clin Pathol. 1999;112:50-56. (Pubitemid 30214735)
85. Nizzoli R, Bozzetti C, Naldi N, et al. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer. 2000;90:61-66. (Pubitemid 30120290)
86. Sianesi M, Bozzetti C, Del RP, et al. Primary breast carcinoma: immunocytochemical and immunohistochemical evaluation of biological parameters. Chir Ital. 2000;52:643-645.
87. Briffod M, Hacene K, Le DV. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol. 2000;13:841-850. (Pubitemid 30643830)
88. Cano G, Milanezi F, Leitao D, et al. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol. 2003;29:207-211. (Pubitemid 37193648)
89. Vesoulis Z, Rajappannair L, Define L, et al. Quantitative image analysis of estrogen receptors in breast fine needle aspiration biopsies. Anal Quant Cytol Histol. 2004;26:323-330. (Pubitemid 40023967)
90. Konofaos P, Kontzoglou K, Georgoulakis J, et al. The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors. Surg Oncol. 2006;15:257-266. (Pubitemid 46771199)
91. Zoppi JA, Rotundo AV, Sundblad AS. Correlation of immunocytochemical and immunohistochemical determination of estrogen and progesterone receptors in breast cancer. Acta Cytol. 2002;46: 337-340. (Pubitemid 34625166)
92. Bajetta E, Celio L, Di LA, et al. Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study. Int J Oncol. 1998;12: 853-858. (Pubitemid 28133578)
93. Jayaram G, Elsayed EM. Cytologic evaluation of prognostic markers in breast carcinoma. Acta Cytol. 2005;49:605-610. (Pubitemid 41667077)
94. Klorin G, Keren R. Prognostic markers in histologic and cytologic specimens of breast cancer. Anal Quant Cytol Histol. 2003;25: 297-302. (Pubitemid 37280762)
95. Makris A, Allred DC, Powles TJ, et al. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997;44:65-74. (Pubitemid 27179770)
96. Suthipintawong C, Leong AS, Chan KW, et al. Immunostaining of estrogen receptor, progesterone receptor, MIB1 antigen, and cerbB- 2 oncoprotein in cytologic specimens: a simplified method with formalin fixation. Diagn Cytopathol. 1997;17:127-133. (Pubitemid 27319131)
97. Tafjord S, Bohler PJ, Risberg B, et al. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Diagn Cytopathol. 2002;26:137-141. (Pubitemid 34195273)
98. Makris A, Powles TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat. 1999;53: 51-59. (Pubitemid 29123619)
99. Muller-Holzner E, Zeimet AG, Daxenbichler G, et al. Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases. Breast Cancer Res Treat. 1993;25:47-55. (Pubitemid 23107735)
100. Nedergaard L, Haerslev T, Jacobsen GK. Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS. 1995;103:20-24.
101. Ozzello L, DeRosa C, Habif DV, et al. An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer. 1991;67:455-462.
102. Paterson DA, Reid CP, Anderson TJ, et al. Assessment of oestrogen receptor content of breast carcinoma by immunohistochemal techniques on fixed and frozen tissue and by biochemical ligand binding assay. J Clin Pathol. 1990;43:46-51. (Pubitemid 20063713)
103. Raymond WA, Leong AS. Oestrogen receptor staining of paraffinembedded breast carcinomas following short fixation in formalin: a comparison with cytosolic and frozen section receptor analyses. J Pathol. 1990;160:295-303. (Pubitemid 20136755)
104. Scharl A, Vierbuchen M, Conradt B, et al. Immunohistochemical detection of progesterone receptor in formalin-fixed and paraffinembedded breast cancer tissue using a monoclonal antibody. Arch Gynecol Obstet. 1990;247:63-71. (Pubitemid 20128535)
105. Snead DR, Bell JA, Dixon AR, et al. Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology. 1993;23: 233-238. (Pubitemid 23281924)
106. Andersen J, Thorpe SM, King WJ, et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffinembedded and frozen sections versus that of steroid-binding assays. Eur J Cancer. 1990;26:442-449. (Pubitemid 20209972)
107. Cavaliere A, Bellezza G, Ferri I, et al. Computer-assisted immunocytochemical determination of breast cancer steroid receptors. Frozen sections vs paraffin sections. Breast. 2001;11: 476-483. (Pubitemid 33150362)
108. Elias JM, Margiotta M, Sexton TR, et al. Immunohistochemical detection of sex steroid receptors in breast cancer using routine paraffin sections: comparison with frozen sections and enzyme immunoassay. J Cell Biochem Suppl. 1994;19:126-133. (Pubitemid 24306458)
109. Fee M, Tobin B, Magee H, et al. Comparison of oestrogen receptor assessment in frozen and paraffin sections. Pathol Res Pract. 1996;192:919-924. (Pubitemid 26393439)
110. Goulding H, Pinder S, Cannon P, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol. 1995;26: 291-294.
111. Ibarra GR, Sananes C, Podeley G, et al. Estrogen receptor immunohistochemistry in formalin-fixed, paraffin-embedded breast tumor tissue: enhanced sensitivity using a monoclonal antibody cocktail. Appl Immunohistochem Mol Morphol. 1995;3: 202-208.
112. Masood S, Dee S, Goldstein JD. Immunocytochemical analysis of progesterone receptors in breast cancer. Am J Clin Pathol. 1991;96:59-63.
113. Masood S, Lu L, Rodenroth N. Potential value of estrogen receptor immunocytochemical assay in formalin-fixed breast tumors. Mod Pathol. 1990;3:724-728.
114. Miller RT, Hapke MR, Greene GL. Immunocytochemical assay for estrogen receptor with monoclonal antibody D753P gamma in routinely processed formaldehyde-fixed breast tissue. Comparison with frozen section assay and with monoclonal antibody H222. Cancer. 1993;71:3541-3546. (Pubitemid 23152662)
115. Stylianodou A, Papadimitriou CS. Immunohistochemical demonstration of estrogen receptors on routine paraffin sections of breast carcinomas: a comparison with frozen sections and an enzyme immunoassay. Oncology. 1992;49:15-21.
116. von Boguslawsky BK. Immunohistochemical detection of progesterone receptors in paraffin sections. A novel method using microwave oven pretreatment. APMIS. 1994;102:641-646.
117. von Wasielewski WR, Mengel M, Nolte M, et al. Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J. 1998;4:33-40. (Pubitemid 28080204)
118. von Wasielewski WR, Mengel M, Wiese B, et al. Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol. 2002;118:675-682. (Pubitemid 37046311)
119. Lee H, Douglas-Jones AG, Morgan JM, et al. The effect of fixation and processing on the sensitivity of oestrogen receptor assay by immunohistochemistry in breast carcinoma. J Clin Pathol. 2002;55:236-238. (Pubitemid 34250915)
120. Delfour C, Roger P, Bret C, et al. RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells. J Mol Diagn. 2006;8:157-169. (Pubitemid 43811238)
121. Nassiri M, Ramos S, Zohourian H, et al. Preservation of biomolecules in breast cancer tissue by a formalin-free histology system. BMC Clin Pathol. 2008;8:1-10.
122. Arber DA. Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol. 2002;10:183-186. (Pubitemid 34553177)
123. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86-92. (Pubitemid 37046374)
124. Jensen V, Ladekarl M. Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer. J Clin Pathol. 1995;48:429-432.
125. Bromley CM, Palechek PL, Benda JA. Preservation of estrogen receptor in paraffin sections. J Histotechnol. 1994;17:115-118. (Pubitemid 24209442)
126. Hendricks JB, Stephen CA, Wilkinson EJ, et al. Estrogen receptor specific (ER1D5) epitope stability in paraffin sections. J Histotechnol. 1996;19:23-25. (Pubitemid 26087422)
127. Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor markerimmunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 1996;88:1054-1059. (Pubitemid 26260491)
128. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol. 1998;51:370-374. (Pubitemid 28289123)
129. DiVito KA, Charette LA, Rimm DL, et al. Long-term preservation of antigenicity on tissue microarrays. Lab Invest. 2004;84:1071-1078. (Pubitemid 39025041)
130. Fergenbaum JH, Garcia-Closas M, Hewitt SM, et al. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004;13:667-672. (Pubitemid 38737907)
131. Mirlacher M, Kasper M, Storz M, et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol. 2004;17:1414-1420. (Pubitemid 39472998)
132. Blind C, Koepenik A, Pacyna-Gengelbach M, et al. Antigenicity testing by immunohistochemistry after tissue oxidation. J Clin Pathol. 2008;61:79-83. (Pubitemid 351158230)
133. Frost AR, Sparks D, Grizzle WE. Methods of antigen recovery vary in their usefulness in unmasking specific antigens in immunohistochemistry. Appl Immunohistochem Mol Morphol. 2000;8: 236-243.
134. Rossi S, Laurino L, Furlanetto A, et al. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol. 2005;124:295-302. (Pubitemid 41060143)
135. Huang Z, Zhu W, Szekeres G, et al. Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol. 2005;13:91-95. (Pubitemid 40283809)
136. Huang Z, Zhu W, Meng Y, et al. Development of new rabbit monoclonal antibody to progesterone receptor (Clone SP2): no heat pretreatment but effective for paraffin section immunohistochemistry. Appl Immunohistochem Mol Morphol. 2006;14:229-233. (Pubitemid 43941191)
137. Bier B, Bankfalvi A, Grote L, et al. Wet autoclave pretreatment for immunohistochemical demonstration of oestrogen receptors in routinely processed breast carcinoma tissue. Histochem J. 1995;27: 148-154.
138. Mote PA, Leary JA, Clarke CL. Immunohistochemical detection of progesterone receptors in archival breast cancer. Biotech Histochem. 1998;73:117-127. (Pubitemid 28317492)
139. Neves JI, Begnami MD, Arias V, et al. Antigen retrieval methods and estrogen receptor immunoexpression using 1D5 antibody: a comparative study. Int J Surg Pathol. 2005;13:353-357. (Pubitemid 41688597)
140. Vassallo J, Pinto GA, Alvarenga JM, et al. Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl Immunohistochem Mol Morphol. 2004; 12:177-182. (Pubitemid 38796461)
141. Balaton AJ, Mathieu MC, Le DV. Optimization of heat-induced epitope retrieval for estrogen receptor determination by immunohistochemistry on paraffin sections. Results of a multicentric comparative study. Appl Immunohistochem. 1996;4:259-263.
142. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26:1059-1065.
143. Yamashita H, Yando Y, Nishio M, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer. 2006;13:74-83.
144. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-J Clin Oncol. 2007;25:3846-3852. (Pubitemid 47477259)
145. Cowen PN, Teasdale J, Jackson P, et al. Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay. Histopathology. 1990;17:319-325. (Pubitemid 20318970)
146. Lockwood CA, Ricciardelli C, Raymond WA, et al. A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer. 1999;84:203-208. (Pubitemid 29256742)
147. Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002;20: 2559-2566. (Pubitemid 34525744)
148. Jalava P, Kuopio T, Huovinen R, et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res. 2005;25(3c):2535-2542. (Pubitemid 41044745)
149. Santeusanio G, Mauriello A, Ventura L, et al. Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule. Appl Immunohistochem Mol Morphol. 2000; 8:275-284.
150. O'Keane JC, Okon E, Moroz K, et al. Anti-estradiol immunoperoxidase labeling of nuclei, not cytoplasm, in paraffin sections, determines estrogen receptor status of breast cancer. Am J Surg Pathol. 1990;14:121-127. (Pubitemid 20039007)
151. Hendricks JB, Wilkinson EJ. Comparison of two antibodies for evaluation of estrogen receptors in paraffin-embedded tumors. Mod Pathol. 1993;6:765-770. (Pubitemid 2014286)
152. Bevitt DJ, Milton ID, Piggot N, et al. New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. J Pathol. 1997;183: 228-232. (Pubitemid 27436029)
153. Huang A, Pettigrew NM,Watson PH. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol. 1996;180: 223-227. (Pubitemid 26370191)
154. Saccani JG, Johnston SR, Salter J, et al. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol. 1994;47:900-905.
155. Nichols GE, Frierson HF Jr Boyd JC, et al. Automated immunohistochemical assay for estrogen receptor status in breast cancer using monoclonal antibody CC4-5 on the Ventana ES. Am J Clin Pathol. 1996;106:332-338. (Pubitemid 26309085)
156. Huang A, Leygue E, Dotzlaw H, et al. Influence of estrogen receptor variants on the determination of ER status in human breast cancer. Breast Cancer Res Treat. 1999;58:219-225. (Pubitemid 30113874)
157. Kleer CG, Wojno KJ, Fields K, et al. Detection of estrogen receptor in carcinomas of the breast using automated immunohistochemistry. Appl Immunohistochem. 1999;7:103-107. (Pubitemid 29382757)
158. Rost NS, Murphy K, Hafer L, et al. Immunochemical analyses of estrogen receptors in human breast tumors by a novel monoclonal estrogen receptor antibody (EVG F9). Steroids. 2000;65:429-436. (Pubitemid 30628371)
159. Press M, Spaulding B, Groshen S, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids. 2002;67:799-813. (Pubitemid 34765669)
160. Kaplan PA, Frazier SR, Loy TS, et al. 1D5 and 6F11: an immunohistochemical comparison of two monoclonal antibodies for the evaluation of estrogen receptor status in primary breast carcinoma. Am J Clin Pathol. 2005;123:276-280. (Pubitemid 40194091)
161. Phillips T, Murray G, Wakamiya K, et al. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol. 2007;15:325-331. (Pubitemid 47329926)
162. Arihiro K, Umemura S, Kurosumi M, et al. Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays. Am J Clin Pathol. 2007;127:356-365. (Pubitemid 46806328)
163. Ibrahim M, Dodson A, Barnett S, et al. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol. 2008;129:398-409. (Pubitemid 352029292)
164. Nedergaard L, Christensen L, Rasmussen BB, et al. Comparison of two monoclonal antibodies for the detection of estrogen receptors in primary breast carcinomas. Pathol Res Pract. 1996;192:983-988. (Pubitemid 26402649)
165. Goldstein NS, Hunter S, Forbes S, et al. Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: the importance of optimizing antibody avidity. Appl Immunohistochem Mol Morphol. 2007;15: 203-207. (Pubitemid 46828230)
166. Cohen C, Unger ER, Sgoutas D, et al. Automated immunohistochemical estrogen receptor in fixed embedded breast carcinomas. Am J Clin Pathol. 1991;95:335-339.
167. Sumiyoshi Y, Shirakusa T, Yamashita Y, et al. Highly sensitive immunohistological study for detection of estrogen receptor in human breast cancer. J Surg Oncol. 2001;76:13-18. (Pubitemid 32128357)
168. Biesterfeld S, Kraus HL, Reineke T, et al. Analysis of the reliability of manual and automated immunohistochemical staining procedures. A pilot study. Anal Quant Cytol Histol. 2003;25:90-96. (Pubitemid 36457584)
169. Navani S, Bhaduri AS. High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction? Indian J Pathol Microbiol. 2005;48:199-201. (Pubitemid 44783483)
170. Regitnig P, Reiner A, Dinges HP, et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Archiv. 2002;441:328-334. (Pubitemid 36015595)
171. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008; 100:1380-1388.
172. Umemura S, Itoh J, Itoh H, et al. Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol. 2004;12:8-13. (Pubitemid 38332312)
173. Detre S, Saclani JG, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:876-878.
174. Aye AT, Mei JC, Fook-Chong S, et al. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology. 2001;33:21-25. (Pubitemid 32222505)
175. Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18Ffluoroestradiol. J Nucl Med. 2008;49:367-374. (Pubitemid 351355201)
176. Sharangpani GM, Joshi AS, Porter K, et al. Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer. J Microsc. 2007; 226:244-255. (Pubitemid 47024246)
177. Bejar J, Sabo E, Misselevich I, et al. Comparative study of computer-assisted image analysis and light- microscopically determined estrogen receptor status of breast carcinomas. Arch Pathol Lab Med. 1998;122:346-352. (Pubitemid 28169380)
178. Kurosumi M. Immunohistochemical assessment of hormone receptor status using a new scoring system (J-Score) in breast cancer. Breast Cancer. 2007;14:189-193.
179. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85: 200-206. (Pubitemid 23046895)
180. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168. (Pubitemid 28144151)
181. McClelland RA, Finlay P, Walker KJ, et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res. 1990;50:3545-3550. (Pubitemid 20194093)
182. Leake R, Barnes D, Pinder S, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol. 2000;53:634-635.
183. Baddoura FK, Cohen C, Unger ER, et al. Image analysis for quantitation of estrogen receptor in formalin-fixed paraffinembedded sections of breast carcinoma. Mod Pathol. 1991;4:91-95.
184. Ballouk F, Boguniewicz A, Ross JS, et al. Image analysis quantification in hormone receptor assay of mucinous carcinoma of the breast. Comparison with biochemical analysis. Anal Quant Cytol Histol. 1995;17:151-156.
185. Layfield LJ, Saria EA, Conlon DH, et al. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance. J Surg Oncol. 1996;61:177-184.
186. Gibney EM, Lawson D, DeRose PB, et al. Image cytometric progesterone receptor quantitation: comparison with visual semiquantitation and cytosolic assay. Appl Immunohistochem. 1998; 6:62-68. (Pubitemid 28311670)
187. Chung GG, Zerkowski MP, Ghosh S, et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest. 2007;87:662-669. (Pubitemid 46920099)
188. Sherman ME, Rimm DL, Yang XR, et al. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer. 2007;121:1079-1085. (Pubitemid 47101646)
189. Lehr HA, Mankoff DA, Corwin D, et al. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 1997;45:1559-1565. (Pubitemid 27465476)
190. Mofidi R, Walsh R, Ridgway PF, et al. Objective measurement of breast cancer oestrogen receptor status through digital image analysis. Eur J Surg Oncol. 2003;29:20-24. (Pubitemid 36181772)
191. Gokhale S, Rosen D, Sneige N, et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2007;15:451-455. (Pubitemid 350307853)
192. Kostopoulos S, Cavouras D, Daskalakis A, et al, Colour-texture based image analysis method for assessing the hormone receptors status in breast tissue sections. Proceedings of the 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society; August 23-26, 2007; Lyon, France..
193. Rothmann C, Barshack I, Gil A, et al. Potential use of spectral image analysis for the quantitative evaluation of estrogen receptors in breast cancer. Histol Histopathol. 2000;15:1051-1057.
194. Aziz DC. Quantitation of estrogen and progesterone receptors by immunocytochemical and image analyses. Am J Clin Pathol. 1992;98:105-111.
195. Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol. 2004;8:23-27. (Pubitemid 38199175)
196. Gorczyca W, Davidian M, Gherson J, et al. Laser scanning cytometry quantification of estrogen receptors in breast cancer. Anal Quant Cytol Histol. 1998;20:470-476. (Pubitemid 29004098)
197. Hatanaka Y, Hashizume K, Nitta K, et al. Cytometrical image analysis for immunohistochemical hormone receptor status in breast carcinomas. Pathol Int. 2003;53:693-699. (Pubitemid 37430936)
198. Kohlberger PD, Breitenecker F, Kaider A, et al. Modified truecolor computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison. Anticancer Res. 1999;19(3B):2189- 2193. (Pubitemid 29392520)
199. Charalambous D, Kitchen PR, Stillwell RG, et al. A comparison between radioligand and immunohistochemical assay of hormone receptors in primary breast cancer. Aust N Z J Surg. 1993;63: 637-641. (Pubitemid 23231539)
200. Francis GD, Dimech M, Giles L, et al. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol. 2007;60:1277-1283. (Pubitemid 350084552)
201. Collins LC, Marotti JD, Baer HJ, et al. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst. 2008;100:218-221. (Pubitemid 351480544)
202. Rhodes A, Jasani B, Balaton AJ, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000;53:688-696.
203. Rhodes A, Jasani B, Balaton AJ, et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000;53:292-301. (Pubitemid 30180402)
204. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53: 125-130. (Pubitemid 30075056)
205. Chebil G, Bendahl PO, Ferno M, Group SSBC, Group NSBC. Estrogen and progesterone receptor assay in paraffin-embedded breast cancer-reproducibility of assessment. Acta Oncol. 2003;42: 43-47. (Pubitemid 36307884)
206. Lambkin HA, Dunne P, McCarthy PM. Standardization of estrogen-receptor analysis by immunohistochemistry: an assessment of interlaboratory performance in Ireland. Appl Immunohistochem. 1998;6:103-107. (Pubitemid 28311677)
207. Layfield LJ, Gupta D, Mooney EE. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methods. Breast J. 2000;6:189-196. (Pubitemid 30347116)
208. Miller K, Ibrahim M, Barnett S, et al. Technical aspects of predictive and prognostic markers in breast cancer: what UK NEQAS data shows. Curr Diagn Pathol. 2007;13:135-149. (Pubitemid 46518122)
209. Wells CA, Sloane JP, Coleman D, et al. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union-an inter-laboratory study. Virchows Archiv. 2004;445:119-128. (Pubitemid 39215542)
210. Thomas J, Hanby A, Pinder S, et al. Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. Breast J. 2008;14:33-38.
211. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004;164:35-42. (Pubitemid 38364587)
212. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med. 2004;351:2817-2826. (Pubitemid 40051905)
213. Esteva FJ, Sahin AA, Cristofanilli M, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with nodenegative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res. 2005;11:3315-3319. (Pubitemid 40627881)
214. Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11(24 Pt 1):8623-8631. (Pubitemid 43005909)
215. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8:R25.
216. Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor- positive breast cancer. Clin Chem. 2007;53:1084-1091. (Pubitemid 46867525)
217. Wolf I, Ben-Baruch N, Shapira-Frommer R, et al. Association between standard clinical and pathologic characteristics and the 21- gene recurrence score in breast cancer patients: a populationbased study. Cancer. 2008;112:731-736. (Pubitemid 351240566)
218. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol. 2006;24:3726-3734. (Pubitemid 46622311)
219. Chang JC, Makris A, Gutierrez MC, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008;108:233-240. (Pubitemid 351311356)
220. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265-7277. (Pubitemid 46202341)
221. Mina L, Soule SE, Badve S, et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat. 2007;103:197-208. (Pubitemid 46789142)
222. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25:1239- 1246. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790..
223. Smith DD, Saetrom P, Snove O Jr, et al. Meta-analysis of breast cancer microarray studies in conjunction with conserved ciselements suggest patterns for coordinate regulation. BMC Bioinformatics. 2008;9:63.
224. Fan C, Oh DS, Wessels L, et al. Concordance among geneexpression- based predictors for breast cancer. New Engl J Med. 2006;355:560-569. (Pubitemid 44200649)